On 18 May 2020, Lipocine Inc. stock identified change of 205.55% away from 52-week low price and recently located move of -73.34% off 52-week high price. It has market worth of $35.9M. LPCN stock has been recorded 81.27% away from 50 day moving average and -27.36% away from 200 day moving average. Moving closer, we can see that shares have been trading 49.73% off 20-day moving average.
Lipocine Inc. (LPCN) recently reported financial results for the first quarter ended March 31, 2020, and provided a corporate update.
First Quarter Ended March 31, 2020 Financial Results
Lipocine stated a net loss of $5.8M, or ($0.14) per diluted share, for the quarter ended March 31, 2020, contrast with a net loss of $3.2M, or ($0.14) per diluted share, for the quarter ended March 31, 2019.
Research and development expenses were $2.5M for the quarter ended March 31, 2020, contrast with $1.9M for the quarter ended March 31, 2019. The increase in research and development expenses during the three months ended March 31, 2020 was primarily Because of increased contract research organization and outside consulting and manufacturing costs for the LPCN 1144 LiFT Phase 2 clinical study in NASH subjects of $1.7M, a $50,000 increase in costs for TLANDO XR and a $56,000 increase in personnel expense. These increases were offset by a $1.2M decrease in costs incurred relating to TLANDO, including the completion of the ABPM study and the filing of the NDA in the first half of 2019 and a $12,000 decrease in contract manufacturing costs for LPCN 1107.
General and administrative expenses were $2.1M for the quarter ended March 31, 2020, contrast with $1.2M for the quarter ended March 31, 2019. The increase in general and administrative expenses during the three months ended March 31, 2020 was primarily Because of a $1.0M increase in legal costs associated with the lawsuit filed against Clarus for patent infringement in April 2019 in addition to costs associated with interference cases filed against Clarus, offset by a $59,000 decrease in personnel costs and a $26,000 decrease in administrative travel expenses.
As of March 31, 2020, Lipocine had $15.6M of unrestricted cash, cash equivalents and marketable investment securities contrast to $14.1M at December 31, 2019. Additionally, the Company had $5.0M of restricted cash, which is required to be maintained as cash collateral under the SVB Loan and Security Contract until TLANDO is accepted by the FDA. The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements through at least February 15, 2021.
The Healthcare sector company, Lipocine Inc. noticed change of 14.96% to $0.92 along volume of 1687204 shares in recent session compared to an average volume of 1329.85K. The stock observed return of 20.52% in 5 days trading activity. LPCN’s shares are at 75.86% for the quarter and driving a -56.99% return over the course of the past year and is now at 107.85% since this point in 2018.